Stock Price Quote

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE1921.00-21.15 (-1.09 %)
PREV CLOSE ( ) 1942.15
OPEN PRICE ( ) 1945.00
BID PRICE (QTY) 1920.10 (24)
OFFER PRICE (QTY) 1924.60 (8)
VOLUME 169
TODAY'S LOW / HIGH ( )1921.00 1949.00
52 WK LOW / HIGH ( )1551.05 2636
NSE1924.60-21 (-1.08 %)
PREV CLOSE( ) 1945.60
OPEN PRICE ( ) 1945.60
BID PRICE (QTY) 1924.10 (1)
OFFER PRICE (QTY) 1926.10 (8)
VOLUME 7113
TODAY'S LOW / HIGH( ) 1919.90 1950.80
52 WK LOW / HIGH ( )1599 2641
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1990
Management Info
C C Paarthipan - Chairman Sridhar Ganesan - Managing Director
Registered Office

Address 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,Perungudi,
Chennai,
Tamil Nadu-600096

Phone 044-24968000 / 8012772888 / 71148000

Email info@caplinpoint.net

Website www.caplinpoint.net

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE, NSE

NEWS

09Dec Caplin Point Laboratories’ arm gets US
Caplin Point Laboratories’ subsidiary -- Caplin Steriles (Caplin) has be..
09Dec Caplin Point Laboratories informs abou
Caplin Point Laboratories has informed that it enclosed Press Release on..
08Dec Caplin Point Laboratories’ arm gets US
Caplin Point Laboratories’ Subsidiary -- Caplin Steriles has received fi..
05Nov Caplin Point Laboratories informs abou
Further to intimation dated 29th October, 2025 Caplin Point Laboratories..
23Oct Caplin Point’s arm gets USFDA’s approv
Caplin Point Laboratories’ Subsidiary -- Caplin Steriles has received fi..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit1025.93394.9
Gross Profit 1290 4416.7
Operating Profit 1350.74665.6
Net Sales 1751.87524.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  1780.00 (2.10%)
M.Cap ( in Cr)849.90
Procter&Gamble Healt (BSE)
peergroup  5715.05 (0.62%)
M.Cap ( in Cr)9374.50
BDH Inds (BSE)
peergroup  435.00 (4.88%)
M.Cap ( in Cr)250.70
Lupin (BSE)
peergroup  2106.40 (0.80%)
M.Cap ( in Cr)96747.70
Onesource Specialty (BSE)
peergroup  1607.05 (0.98%)
M.Cap ( in Cr)18362.84

Shareholding Pattern

PROMOTERS 70.57%
NON-INSTITUTION 20.82%
MUTUAL FUNDS/UTI 1.79%
FI/BANKS/INSURANCE 0.23%
GOVERNMENT 0%
FII 0%

About Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd. was incorporated in the year 1990. Its today's share price is 1921. Its current market capitalisation stands at Rs 14746.27 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7524.1 Cr and Total Income of Rs.8870 Cr. The company's management includes S Deenadhayalan, R Vijayaraghavan, R Nagendran, CK Gariyali, Sridhar Ganesan, C C Paarthipan, G Venkatram.

It is listed on the BSE with a BSE Code of 524742 , NSE with an NSE Symbol of CAPLIPOINT and ISIN of INE475E01026. It's Registered office is at 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,PerungudiChennai-600096, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Brahmayya & Co, CNGSN & Associates, CNGSN & Associates LLP, M Raghunath & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.